CgA和PCA3的表达在前列腺癌患者诊断中的应用研究

摘要

目的 探讨血液及尿液中CgA、PCA3的表达在列腺癌患者诊断中的临床应用意义.方法 采用随机数字表法随即抽取62例患者和62例健康受检者,试验组为前列腺癌患者,对照组为健康受检者,对两组受检者血液及尿液中CgA、PCA3进行定量检测,讨论其在前列腺癌患者的诊断中的临床意义.结果 前列腺癌组的CgA、PCA3阳性表达率明显高于对照组的健康受检者,且前列腺癌患者CgA值会随着病情的进展而增加,健康受检者CgA值基本不变,差异具有统计学意义(P＜0.05).结论 CgA、PCA3的组织特异性阳性表达可对前列腺癌的诊断提供可靠的依据,可以成为前列腺癌的肿瘤标志物,显著提高前列腺癌诊断的敏感度,值得进一步推广.%Objectives To discuss CgA and PCA3 expressions' (in blood and urine) and their clinical application in diagnosis of prostatic cancer.Methods 62 patients affected with prostatic cancer and 62 persons having health examinations were randomly selected and classified into two groups.Those affected with prostatic cancer were in the experimental group and those having health-examinations were in the control group.CgA and PCA3 expressions in blood and urine were quantitatively measured to discuss the clinical value in diagnosis of prostatic cancer.Results Positive expression rates of CgA and PCA3 in the experimental group were obviously higher than those of the control group.CgA value in the experimental group increased as the disease progressed,whereas there were no changes basically in the control group (P＜0.05).Conclusions CgA and PCA3 specificity and positive expressions can provide reliable evidence for diagnosis of prostatic cancer,so that they can be used as a tumor marker to improve diagnostic sensitivity of prostatic cancer and is worthy of clinical promotion.